P. D. Hinduja Hospital Strengthens Orthopaedic Care with CORI Surgical System for Robotic-Assisted Knee and Hip Replacement

IMT News Desk
IMT News Desk
· 2 min read
P. D. Hinduja Hospital has introduced the next-generation CORI Surgical System for robotic-assisted knee and hip replacement

P. D. Hinduja Hospital & Medical Research Centre strengthens its orthopaedic care capabilities with the advanced, next-generation CORI Surgical System for robotic-assisted knee and hip replacement surgeries at both its Mahim and Khar units.

The CORI Surgical System, developed by Smith+Nephew, is a handheld robotic-assisted platform that enables surgeons to plan and perform total knee, partial knee, hip and complex revision joint replacement surgeries with enhanced accuracy and real-time intraoperative data. Unlike many conventional robotic systems, the platform does not require a pre-operative CT scan, thereby reducing radiation exposure for patients while making the surgical workflow more efficient and patient-friendly.

The technology maps the patient’s knee or hip anatomy during surgery and assists surgeons in creating a highly personalised surgical plan tailored to the patient’s unique anatomy. It also provides real-time data and haptic feedback, helping surgeons achieve millimetre-level precision while protecting surrounding healthy bone and soft tissues. This allows for more accurate implant positioning, improved joint alignment and stability, controlled bone preparation and a more natural feel after surgery.

As a special introductory offering, robotic-assisted knee and hip replacement surgeries using the CORI Surgical System will be provided at no additional cost for a limited period at P. D. Hinduja Hospital & MRC.

Mr. Gautam Khanna, CEO, P. D. Hinduja Hospital & Medical Research Centre, said, “Offering the advanced CORI robotic-assisted joint replacement system at P. D. Hinduja Hospital marks another important step in strengthening our orthopaedic capabilities. This technology enables our clinicians to deliver more precise, personalised and data-driven care while improving patient outcomes and recovery experience.”

Dr. Sanjay Agarwala, Director, Professional Services and Section Head, Orthopaedics & Traumatology, P. D. Hinduja Hospital & Medical Research Centre, said, “The CORI Surgical System allows surgeons to take a far more personalised and precise approach to joint replacement surgery. The technology provides real-time information during surgery, helping us make informed decisions regarding implant positioning, alignment, and tissue balance. The robotic system does not replace the surgeon; rather, it enhances surgical judgement and precision through advanced computation and real-time feedback.”

With this offering, P. D. Hinduja Hospital & Medical Research Centre continues to integrate globally advanced technologies with clinical expertise to deliver personalised, precise, and patient-centric care.

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk